A phase II study of efficacy and safety of Pegasys in patients with Chronic Phase Chronic Myeloid Leukaemia in PCR+ve complete or near complete cytogenetic remission on Glivec at 600 mg daily or maximum tolerated dose

DOI number 10.58109/y6nv-ef03
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)

Australasian Leukaemia and Lymphoma Group (ALLG)

Kerry Taylor (Mater Adult Hospital Brisbane)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 21 patients with newly diagnosed CML
  • Combination of Pegasys and Glivec treatment
  • Demographic data
  • Diagnostic data
  • Treatment data
  • Outcome data

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)

Cancer therapy (excl. chemotherapy and radiation therapy)

ANZCTR Reference ACTRN12605000041651
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au